Sucampo Pharmaceuticals Inc. (SCMP) Shares Sold by Prudential Financial Inc.
Prudential Financial Inc. reduced its stake in shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) by 3.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 433,653 shares of the biopharmaceutical company’s stock after selling 16,900 shares during the period. Prudential Financial Inc. owned approximately 1.01% of Sucampo Pharmaceuticals worth $4,757,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the stock. BlackRock Fund Advisors raised its position in shares of Sucampo Pharmaceuticals by 3.1% in the first quarter. BlackRock Fund Advisors now owns 1,630,036 shares of the biopharmaceutical company’s stock valued at $17,816,000 after buying an additional 48,420 shares during the last quarter. Quantbot Technologies LP raised its position in Sucampo Pharmaceuticals by 850.4% in the second quarter. Quantbot Technologies LP now owns 14,903 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 13,335 shares in the last quarter. Princeton Alpha Management LP acquired a new position in Sucampo Pharmaceuticals during the second quarter worth approximately $138,000. Spark Investment Management LLC raised its position in Sucampo Pharmaceuticals by 120.7% in the first quarter. Spark Investment Management LLC now owns 140,388 shares of the biopharmaceutical company’s stock worth $1,534,000 after buying an additional 76,788 shares in the last quarter. Finally, Boston Partners raised its position in Sucampo Pharmaceuticals by 36.6% in the second quarter. Boston Partners now owns 238,519 shares of the biopharmaceutical company’s stock worth $2,617,000 after buying an additional 63,965 shares in the last quarter. 40.64% of the stock is currently owned by institutional investors.
Shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) opened at 12.84 on Friday. The firm has a market capitalization of $549.68 million, a P/E ratio of 45.05 and a beta of 1.57. The stock has a 50 day moving average of $12.40 and a 200-day moving average of $11.57. Sucampo Pharmaceuticals Inc. has a 1-year low of $9.59 and a 1-year high of $21.27.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.01. Sucampo Pharmaceuticals had a return on equity of 42.18% and a net margin of 6.65%. The business had revenue of $52 million for the quarter, compared to analysts’ expectations of $48.33 million. During the same period in the previous year, the business posted $0.21 EPS. The firm’s quarterly revenue was up 49.1% compared to the same quarter last year. On average, equities analysts expect that Sucampo Pharmaceuticals Inc. will post $1.03 earnings per share for the current year.
A number of research firms recently commented on SCMP. Maxim Group reaffirmed a “buy” rating on shares of Sucampo Pharmaceuticals in a research report on Monday, July 11th. Mizuho reaffirmed a “buy” rating on shares of Sucampo Pharmaceuticals in a research report on Monday, July 11th. Vetr raised shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $14.00 price target on the stock in a research report on Thursday, September 29th. Roth Capital reaffirmed a “buy” rating on shares of Sucampo Pharmaceuticals in a research report on Tuesday, July 12th. Finally, Jefferies Group lowered their price target on shares of Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating on the stock in a research report on Thursday, August 4th. Five research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $18.73.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP).
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.